Clinical Trials
15 trialsNCT05364944 2025-11-17
OXTEND-01
Debiopharm International SA
Phase 1 Terminated
NCT01794793 2024-10-01
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
Phase 4 Completed
NCT02419664 2022-03-31
Ga-68-DOTATOC -PET in the Management of Pituitary Tumours
Göteborg University
Phase 3 Terminated
NCT01861717 2021-09-30
A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
Saint John's Cancer Institute
Phase 4 Terminated
NCT00446082 2020-12-21
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Novartis
Phase 1 Completed
NCT04529356 2020-08-27
The TMS Treatment for Postoperative Headache in GH Tumor
Huashan Hospital
Phase NA Unknown
NCT02354508 2019-12-10
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Novartis
Phase 3 Completed
NCT01673646 2019-09-16
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
Novartis
Phase 2 Completed
NCT01137682 2018-04-05
PAOLA
Novartis
Phase 3 Completed
NCT03439709 2018-03-01
MERGE
Samsung Medical Center
Phase 3 Unknown
NCT02299089 2017-12-15
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
Camurus AB
Phase 2 Completed
NCT00376064 2017-03-06
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Novartis
Phase 4 Completed
NCT01029275 2014-07-31
SAPORO
University Hospital, Rouen
Phase NA Completed
NCT00001860 2008-03-04
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00461149 2007-04-17
HDacro
Federico II University
Phase 4 Completed